SCHEDULE: Armistice Capital Discloses 4.99% Stake in Medicus Pharma
Beneficial Ownership Disclosure (Schedule 13G)
Armistice Capital, LLC and Steven Boyd have disclosed a passive 4.99% beneficial ownership stake in Medicus Pharma Ltd., totaling 935,724 common shares as of June 30, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 935,724 common shares of Medicus Pharma Ltd.
- This ownership represents 4.99% of Medicus Pharma Ltd.'s common shares outstanding.
- The filing is a Schedule 13G, indicating a passive investment where shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both reporting persons share voting and dispositive power over the 935,724 shares.
Sentiment
Score: 5
Explanation: The filing is a routine Schedule 13G disclosure of passive beneficial ownership, indicating no immediate positive or negative implications for the company's operations or financial performance.
Positives
- Not applicable for this type of filing, as a Schedule 13G primarily discloses passive ownership and does not contain operational or financial performance details.
Negatives
- Not applicable for this type of filing, as a Schedule 13G primarily discloses passive ownership and does not contain operational or financial performance details.
Risks
- Not applicable for this type of filing, as a Schedule 13G primarily discloses passive ownership and does not detail company-specific risks.
Future Outlook
Not applicable for this type of filing, as a Schedule 13G primarily discloses passive ownership and does not provide forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of a passive investment stake by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive investor's stake in the company.
- Market: Informs the market of a notable institutional investor's position, which can be perceived as a signal of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (reporting date for ownership). |
| 08/14/2025 | Date of signing the Schedule 13G filing. |
Keywords
Medicus Pharma, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common shares, investment adviser, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.